Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Incyte Corporation
Washington University School of Medicine
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Incyte Corporation
Incyte Corporation
Incyte Corporation
Incyte Corporation
Incyte Corporation
Incyte Corporation
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Columbia University
Stanford University
University of California, San Francisco
Roswell Park Cancer Institute
Incyte Corporation
Incyte Corporation
Incyte Corporation
University of California, Davis
Incyte Corporation
Incyte Corporation
Incyte Corporation
University of Chicago
Georgetown University
Incyte Corporation
Aduro Biotech, Inc.
Fred Hutchinson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute